Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/E of 10.0 — trading at a low earnings multiple
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 894.3% — good return on equity
- Revenue growing at 7% annually
Bausch Health Companies Inc. (BHC) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $1.8 billion . Key value metrics: P/E ratio 10.0, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Bausch Health Companies Inc. — Fundamental Analysis Summary
Bausch Health Companies Inc. (BHC) trades at a trailing P/E of 10.0x — 61% below the Healthcare sector average of 25.3x.
On financial health, BHC shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 894.3% (sector average: -19.8%).
StockPik's composite Value Score for BHC is 90/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BHC shows revenue growing at 7% year-over-year, with earnings growing at 441%.